Active, not recruitingPhase 3NCT05185843

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

Studying Familial lipoprotein lipase deficiency

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Ionis Pharmaceuticals, Inc.
Intervention: Olezarsen(drug)
Enrollment: 24 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2027

Study locations (11)

Diabetes/Lipid Management & Research Center, Huntington Beach, California, United States
Excel Medical Clinical Trials, LLC, Boca Raton, Florida, United States
University of Michigan, Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes (MEND), Ann Arbor, Michigan, United States
University of Rochester School of Medicine, Rochester, New York, United States
Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada
ARC Biosystems, Clinical Assessment Unit (CAU), Vancouver, British Columbia, Canada
St. Boniface General Hospital, Winnipeg, Manitoba, Canada
Ecogene-21, Chicoutimi, Quebec, Canada
Clinique des Maladies Lipidiques de Quebec Inc., Québec, Quebec, Canada
Centre Hospitalier Universite de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada
Karolinska University Hospital Huddinge, Stockholm, Sweden

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05185843 on ClinicalTrials.gov

Other trials for Familial lipoprotein lipase deficiency

Additional recruiting or active studies for the same condition.

See all trials for Familial lipoprotein lipase deficiency →

← Back to all trials